Niravam en es it fr

Categoria

Niravam Marchi, Niravam Analoghi

Niravam Marchi miscela

  • No information avaliable
  • Niravam Formula chimica

    C17H13ClN4

    Niravam RX link

    http://www.rxlist.com/cgi/generic/alpraz.htm

    Niravam FDA foglio

    Niravam FDA

    Niravam DMS (foglio di materiale di sicurezza)

    Niravam MSDS

    Niravam Sintesi di riferimento

    JB Hester, US Pat. 3.987.052 (1976).

    Niravam Peso molecolare

    308.765 g/mol

    Niravam Temperatura di fusione

    228-228.5oC

    Niravam H2O Solubilita

    40 mg / L a pH 7, 12 mg / ml a pH 1,2

    Niravam Stato

    Solid

    Niravam LogP

    4.251

    Niravam Forme di dosaggio

    Compresse (mg 0,25, 0,5, 1 o 2)

    Niravam Indicazione

    Per la gestione del disturbo d'ansia o di breve termine dei sintomi di ansia e per il trattamento del disturbo di panico, con o senza agorafobia.

    Niravam Farmacologia

    Alprazolam, una benzodiazepina, è utilizzato nel trattamento del disturbo di panico e disturbo d'ansia. A differenza di clordiazepossido, clorazepato, e prazepam, alprazolam ha una più breve emivita e metaboliti con attività minima. Come altre benzodiazepine triazolo come triazolam, alprazolam possono avere interazioni farmacologiche significative tra i epatico citocromo P-450 isoenzima 3A4. Clinicamente, tutte le benzodiazepine causano una relazione dose- relativi nervoso centrale attività depressiva sul sistema che varia da lieve compromissione delle prestazioni compito di ipnosi. A differenza di altre benzodiazepine, alprazolam può anche avere una certa attività antidepressivi, anche se evidenza clinica di questa che manca.

    Niravam Assorbimento

    Immediatamente assorbito nel tratto gastrointestinale. La biodisponibilità è del 80-90%.

    Niravam Tossicita

    Orale, mouse: LD50 = 1020 mg / kg. Sintomi di sovradosaggio includono confusione, coma, compromissione della coordinazione, sonnolenza, e tempo di reazione è rallentata.

    Niravam Informazioni paziente

    Alprazolam is used for the treatment of anxiety, panic disorder, and insomnia. Inform your physican if you are pregnant or nursing. Alprazolam may cause dizziness and drowsiness; use caution while driving or operating hazardous machinery. Do not take any other sedating drugs or drink alcohol while taking this medication. Alprazolam may be habit forming. Withdrawal symptoms may occur after you stop taking it. Alprazolam may be taken with or without food.

    For All Users of Alprazolam

    To assure safe and effective use of benzodiazepines, all patients prescribed alprazolam should be provided with the following guidance. In addition, panic disorder patients, for whom doses greater than 4 mg/day are typically prescribed, should be advised about the risks associated with the use of higher doses.

    1. Inform your physician about any alcohol consumption and medicine you are taking now, including medication you may buy without a prescription. Alcohol should generally not be used during treatment with benzodiazepines.

    2. Not recommended for use in pregnancy. Therefore, inform your physician if you are pregnant, if you are planning to have a child, or if you become pregnant while you are taking this medication.

    3. Inform your physician if you are nursing.

    4. Until you experience how this medication affects you, do not drive a car or operate potentially dangerous machinery, etc.

    5. Do not increase the dose even if you think the medication "does not work anymore" without consulting your physician. Benzodiazepines, even when used as recommended, may produce emotional and/or physical dependence.

    6. Do not stop taking this medication abruptly or decrease the dose without consulting your physician, since withdrawal symptoms can occur.

    Additional Advice for Panic Disorder Patients

    The use of alprazolam at doses greater than 4 mg/day, often necessary to treat panic disorder, is accompanied by risks that you need to carefully consider. When used at high doses greater than 4 mg/day, which may or may not be required for your treatment, alprazolam has the potential to cause severe emotional and physical dependence in some patients and these patients may find it exceedingly difficult to terminate treatment. In two controlled trials of 6 to 8 weeks duration where the ability of patients to discontinue medication was measured, 7-29% of patients treated with alprazolam did not completely taper off therapy. In a controlled postmarketing discontinuation study of panic disorder patients, the patients treated with doses of alprazolam greater than 4 mg/day had more difficulty tapering to zero dose than patients treated with less than 4 mg/day. In all cases, it is important that your physician help you discontinue this medication in a careful and safe manner to avoid overly extended use of alprazolam.

    In addition, the extended use at doses greater than 4 mg/day appears to increase the incidence and severity of withdrawal reactions when alprazolam is discontinued. These are generally minor but seizure can occur, especially if you reduce the dose too rapidly or discontinue the medication abruptly. Seizure can be life-threatening.

    Niravam Atto interessato organismi

    Gli esseri umani e altri mammiferi